FDA Extends Abbott’s Infinity DBS System Approval to Target Additional Brain Region

FDA Extends Abbott’s Infinity DBS System Approval to Target Additional Brain Region
The U.S. Food and Drug Administration (FDA) has expanded Abbott’s Infinity Deep Brain Stimulation (DBS) system approval to target a brain region critical for motor functions — the globus pallidus — as a way to lessen motor symptoms in Parkinson’s disease patients who still show impairments after medication. This extended approval makes Abbott’s Infinity the only directional DBS system approved to target ... read more
Source: Parkinson’s News TodayPublished on 2020-01-28By Patricia Inacio, PhD